valu usd unless otherwis note
inflect stock come overhang set lift
newco stori emerg
view range-bound sinc announc upjohn deal
understand given perceiv overhang around
pend guidanc updat concern cut sharehold turnov
mid-year close holder share issu well
understood close approach soon address
take conserv stanc newco ebitda rais price
target ahead expect inflect
primari reason stock range-bound first
investor concern around pro-forma number reduct
newco viatri come believ alreadi lower buysid
expect updat newco ebitda take
conserv stand trough ebitda billion
grow thereaft back meaning lower norvasc/
lipitor china contribut model exhibit off-set come
synergi modest stand-alone growth exhibit second concern
anticip sharehold turnov distribut newco
equiti holder fair expect along demand new
fund well ie income/dividend etc
think set becom better appreci
five driver believ buysid expect alreadi low
street pro-forma model stale synergi provid support
stabil ii even lower ebitda newco trade
ebitda even cut ebitda billion abl
support new dividend yield iii leverag target
end could shift focu back price-to-earnings lower ep
follow re-domicil delawar netherland board chang
add ian read jame kilt notabl
thu far de-coupl gener peer newco us gener revenu
pro-forma limit opioid exposur could help
watch focu guidanc updat deal close
expect much new jan conferences/meet
instead anticip stand-alone guidanc feb
histor provid first time guidanc late jan expect
upjohn color though watch potenti earli color
word anticip color stand-alone
upjohn busi jan/feb provid direct color
pro-forma outlook formal newco guidanc like updat
deal close mid-year though believ could come
deal close serv import catalyst want front
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
base case scenario see stock price impli
price-to-earnings ep
announc combin pfe upjohn off-
patent busi grow diversifi myl revenu
base beyond us gener term agreement
holder combin entiti newco
domicil us govern delawar
law invest thesi larg unchang
pre-announc one best generic/
biosimilar pipelin industri believ
deliv above-averag growth moreov cautious
optimist newco deliv posit chang
corpor govern perspect need born
follow primari driver outperform
thesi stock
face mani sector headwind
pressur peer given diversif activ
reposit think see growth improv
come year
sever import pipelin catalyst
myl/upjohn newco trade combin ebitda
drive support improv sentiment
full synergi captur
long-term growth outlook appear stabl increasingli
steadi new gener approv activ high-single-digit
us gener eros base busi
continu ramp recent new product launch
gener copaxon fulphila gener advair
plan combin pfe upjohn busi
add diversif creat signific
oper effici greater scale target
least billion annual cost synergi
risk view delay around pipelin convers and/
lower-than-expect uptak new launch
impair us base busi risk anoth step-
ebitda contribut delay upjohn deal close
and/or integr issu prevent newco hit
financi target inopportun use cash boost
upcom potenti catalyst event focu
deal close pfe upjohn busi expect
launch progress major new launch gener
copaxon fulphila wixela addit accret use
capit debt pay-down
upsid scenario see valu impli price-to-earnings
ep
myl/upjohn newco trade combin ebitda
higher expect synergi captur
inflect higher gener approv activ continu
limit competit high-valu gener greater-
downsid scenario see valu impli price-to-earnings
ep
myl/upjohn trade combin ebitda
greater competit pressur across us gener
portfolio lead lower expect new launch uptak
slowdown ou fail off-set pressur us
failur maintain steadi pipelin convers off-set
new pro-forma analysi take conserv approach outlook
exhibit updat pro-forma analysi newco ebitda billion grow beyond
forma current pro forma adj ebitda ebitda ep upjohn pro forma revenu upjohn guidanc ebitda margin per guid combin pro forma revenu add cost per year reach least billion total combin pro-forma adj ebitda forma ebitda margin depreci actual upjohn estimateless legaci lless newco assum cost newco debt annual de-leverpre-tax incom assum tax re-domicil us current ratesassum tax net incom share count impli base pro forma ownershipnewco forma assumptionscom share friday januari share current share outstand market cap pre-deal close newco deal specif newco share impli share count base state post deal ownershipimpli equiti valu equiti valu pre-deal valuat levelimpli equiti valu price target impli ev/ebitda pro-forma forecast impli equiti valu teva valuat levelimpli equiti valu structurecom exist net new debt total newco net debt target total debt close consist paydown cf forma capit gross leverag end
exhibit stand-alone
 incom guid hsd growth north guid msd growth eurest guid msd growth rowoth gener total revenu guid billioncost gross profit guid guid total revenuessg guid total revenuesoper incom incom incom tax incom guid incom prefer dividend adjust net guid billionep adjust guid dilut share guid million guid billion growth ebitda analysi margin guid guid total guid total revenuesoper expens guid net incom pharmaceuticals/specialti
price target base equal price-to-earnings ev/ebitda multipl appli newco
estim use target multipl respect result
gener price target framework taken trough price-to-earnings valuat
histor averag ev/ebitda valuat made adjust base company-specif
attribut ev/ebitda incorpor opioid liabil within capit structur
price target modestli valuat level trade pre-deal announc
sector histor averag multipl reflect continu challeng
industri impli return price target opportun upsid support
risk rate price target
risk rate price target includ limit delay around pipelin
convers slower expect new launch uptak impair us
base busi delay upjohn deal close and/or integr issu inopportun
use cash boost leverag and/or impair sharehold valu
lead global gener manufactur base pittsburgh pennsylvania employ
approxim peopl global compani found transform
last sever year notabl acquisit merck kgaa
compani benefit differ revenu sourc help grow
eu auster headwind us comp strength recent year
